Home › Research › Treatments
An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects
Rawal S, Wildsmith KR, Aluri J, Yagi T, Chang MK, Niu H, Zhou J, Horie K et al.. Alzheimer disease and associated disorders, 2025-07-17
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Etalanetug (E2814), an anti-tau monoclonal antibody (mAb), is intended to inhibit spreading of pathologic tau species by binding to the microtubule binding region (MTBR). It is being developed as a potential disease-modifying therapy for Alzheimer disease. Methods This randomized, placebo-controlled study comprised of 2 parts: single ascending doses evaluating 5 etalanetug doses and multiple ascending doses evaluating 4 fixed doses in each cohort, 8 healthy subjects were randomized (3:1) to single etalanetug dose or placebo. Safety, pharmacokinetics (PK), antidrug antibodies (ADA), and target engagement (TE) were assessed. Results Etalanetug was safe and well-tolerated following single and multiple infusions. After single-dose and multiple-dose administration, serum exposure of etalanetug increased in a dose-related manner. Serum-to-cerebrospinal fluid (CSF) concentration ratio at week 12 was ∼0.1% to 0.3% and ∼1% following single and multiple dosing, respectively. Mean t ½ was ∼19 to 25 days independent of dose and time. etalanetug immunogenicity was minimal, with low titers and no impact on PK. TE was demonstrated; CSF concentrations of etalanetug between 100 and 200 ng/mL saturated binding of MTBR-tau299 at 82.1% and binding of MTBR-tau354 at 64.9%. Conclusion Etalanetug presented an adequate safety and immunogenicity profile in healthy adults. PK was comparable to other mAbs. Etalanetug demonstrated target engagement by binding to MTBR tau species.
What this study adds
Evidence grade: High
This is a trial. This was a first-in-human study in healthy volunteers, not in people with Alzheimer's disease, so it cannot yet show any effect on treating or preventing the disease. Reported effect size: 0.1% to 0.3%; 82.1%; 64.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rawal, S., Wildsmith, K. R., Aluri, J., Yagi, T., Chang, M. K., Niu, H., et al. (2025). An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects. Alzheimer disease and associated disorders. https://doi.org/10.1097/wad.0000000000000680
Vancouver
Rawal S, Wildsmith KR, Aluri J, Yagi T, Chang MK, Niu H, et al. An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects. Alzheimer disease and associated disorders. 2025. doi:10.1097/wad.0000000000000680. PMID: 40673737.
BibTeX
@article{rawal2025-40673737,
author = {Rawal, S. and Wildsmith, K. R. and Aluri, J. and Yagi, T. and Chang, M. K. and Niu, H. and Zhou, J. and Horie, K. and others},
title = {{An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects}},
journal = {Alzheimer disease and associated disorders},
year = {2025},
doi = {10.1097/wad.0000000000000680},
pmid = {40673737},
url = {https://doi.org/10.1097/wad.0000000000000680}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Etalanetug was safe and well-tolerated following single and multiple infusions.
- TE was demonstrated; CSF concentrations of etalanetug between 100 and 200 ng/mL saturated binding of MTBR-tau299 at 82.1% and binding of MTBR-tau354 at 64.9%.
- Etalanetug demonstrated target engagement by binding to MTBR tau species.
Why it matters
This was a first-in-human study in healthy volunteers, not in people with Alzheimer's disease, so it cannot yet show any effect on treating or preventing the disease. It showed the antibody was safe and well tolerated and bound its target tau in spinal fluid, which supports further testing but does not demonstrate clinical benefit.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Effect size0.1% to 0.3%; 82.1%; 64.9%
- Evidence strengthHigh
How this study scored 66/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 3 / 7 | Cited 21 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 11.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Larisa Reyderman: h-index 30 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40673737) |
| Free to read | 2 / 2 | Free to read |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1097/wad.0000000000000680
- PubMed: 40673737
- Original source →
- Free full text: Alzheimer Disease & Associated Disorders →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.